ALGS

Aligos Therapeutics (ALGS)

Aligos Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ALGS

1 2 3 4 5 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/05	15 : 30	GlobeNewswire Inc.	Aligos Therapeutics Presents Positive Data at the EASL Congress 2024	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/06/01	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/05/23	05 : 05	GlobeNewswire Inc.	Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/05/23	05 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/05/21	21 : 00	GlobeNewswire Inc.	Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/05/16	06 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/05/08	05 : 13	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/05/08	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/05/08	05 : 05	GlobeNewswire Inc.	Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/05/01	05 : 05	GlobeNewswire Inc.	Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/04/26	05 : 05	GlobeNewswire Inc.	Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/04/25	21 : 00	GlobeNewswire Inc.	Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/04/09	21 : 00	GlobeNewswire Inc.	Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/04/03	21 : 00	GlobeNewswire Inc.	Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/03/27	21 : 00	GlobeNewswire Inc.	Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/03/18	21 : 00	GlobeNewswire Inc.	Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/03/13	05 : 05	GlobeNewswire Inc.	Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/03/06	06 : 05	GlobeNewswire Inc.	Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/03/05	07 : 44	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/03/05	07 : 42	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/02/29	07 : 35	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/02/29	07 : 33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/02/29	07 : 31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/02/26	22 : 00	GlobeNewswire Inc.	Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/02/20	22 : 00	GlobeNewswire Inc.	Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/02/13	22 : 00	GlobeNewswire Inc.	Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/01/30	21 : 04	Edgar (US Regulatory)	Form SC TO-I - Tender offer statement by Issuer	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/01/25	20 : 12	Edgar (US Regulatory)	Form SC TO-C - Written communication relating to an issuer or third party	NASDAQ:ALGS	Aligos Therapeutics Inc
2024/01/25	20 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALGS	Aligos Therapeutics Inc
2023/11/29	06 : 01	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:ALGS	Aligos Therapeutics Inc